| Literature DB >> 29174587 |
M A S Malaquias1, L A Oyama2, P C Jericó2, I Costa3, G Padilha3, S Nagashima2, M Lopes-Pacheco3, C L K Rebelatto4, P V Michelotto4, D G Xisto3, P R S Brofman4, P R M Rocco3, L de Noronha2.
Abstract
Asthma is a heterogeneous disease characterised by chronic airway inflammation. One of the most devastating consequences of this inflammatory process is the generation of reactive oxygen and nitrogen species responsible for oxidative stress. The aim of this study is to analyse the efficiency of treatment with human bone marrow-derived mesenchymal stromal cells (hMSC) in maintaining the oxidative balance in a murine model of allergic asthma by quantifying nitrotyrosine in lung tissues. After confirmation of asthma in the experimental model, samples of lung parenchyma were submitted to immunohistochemical assessment. Intravenous administration of hMSC reduced the levels of nitrotyrosine in the ASTHMA-hMSC group compared to those in the ASTHMA-SAL group. In conclusion, therapeutic administration of hMSC had a beneficial effect on oxidative stress, reducing the levels of nitrotyrosine in lung tissues in a model of allergic asthma.Entities:
Keywords: Asthma; Mesenchymal cells; Nitrotyrosine; Oxidative stress; Peroxynitrite
Mesh：
Substances：
Year: 2017 PMID： 29174587 DOI： 10.1016/j.aller.2017.06.003
Source DB: PubMed Journal: Allergol Immunopathol (Madr) ISSN： 0301-0546 Impact factor: 1.667